There have been tremendous advances in our understanding of cancer from the application of molecular biology over the past decade. The disease is caused by a series of defects in the genes that accelerate growth-oncogenes-and those that slow down cellular turnover-tumour suppressor genes. The proteins they encode provide a promising hunting ground in which to design and test new anticancer drugs. Several treatment strategies are now under clinical trial entailing direct gene transfer. These include the use of gene marking to detect minimal residual disease, the production of novel cancer vaccines by the insertion of genes which uncloak cancer cells so making them visible to the host's immune system, the isolation and coupling of cancer specific molecular switches upstream of drug activating genes, and the correction of aberrant oncogenes or tumour suppressor genes. The issues in these approaches are likely to have a profound impact on the management of cancer patients as we enter the next century.
机构:
UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USAUNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA
机构:
UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USAUNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA